



CALIFORNIA ACADEMY OF
FAMILY PHYSICIANS
STRONG MEDICINE FOR CALIFORNIA

California Academy of Family Physicians | 2018

Reproductive Health Care:



Conversations for Family Physicians
and Their Patients



Shannon Connolly, MD



- Planned Parenthood
- Orange and San Bernardino Counties
- Los Angeles, CA

The CAFP Committee on Continuing Professional Development is responsible for management and resolution of conflict for any individual who may have an influence on content, who has served as faculty, or who may produce CME/CPD content for the CAFP.

It is the policy of CAFP to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities.

Shannon Connolly, MD declares that neither she nor members of their immediate family have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation.

Shannon Connolly, MD may discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved OR investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Objectives

By the end of this session, participants will be able to:

- Open conversations with patients about reproductive life planning by asking One Key Question®.
- Engage patients in patient-centered counseling about their reproductive life planning, including prescribing appropriate contraceptive options and emergency contraception, and managing chronic medical conditions using evidence-based guidelines.
- Discuss and correct reproductive health myths.



Products discussed in this presentation

BRAND NAME PRODUCTS

Brand Name

Liletta and Mirena
 Kyleena
 Skyla
 ParaGard
 Nexplanon
 Depo-Provera
 Ella
 Plan B One Step

Generic Name

Levonorgestrel 52mg
 Levonorgestrel 19.5mg
 Levonorgestrel 13.5mg
 copper IUD
 etonogestrel
 medroxyprogesterone
 Ulipristal
 Levonorgestrel 1.5 mg

GENERIC PRODUCTS

Levonorgestrel
 Etonogestrel
 Medroxyprogesterone
 Ulipristal



SCHD Internal Medicine Sample Query Mode

PAT: 10033 Williams, Judy RES: 7 LOC: REA:

LEN: wednesday 03/12/2008 TIME: TYPE: A SLIP:

NOTE:

Our days are packed,
and we need to recognize that most patients don't come to an appointment specifically FOR contraception.

The conversation may be an "oh by the way" or "one more thing" at the end of the visit.

Being proactive, and adding a simple question to each visit can help you open conversations about reproductive health planning that won't overwhelm you or your patient.

Our days are packed,
and we need to recognize that most patients don't come to an appointment specifically FOR contraception.

The conversation may be an “oh by the way” or “one more thing” at the end of the visit.

Being proactive, and adding a simple question to each visit can help you open conversations about reproductive health planning that won't overwhelm you or your patient.

Did You Know?

- **45%** of US pregnancies are unintended.
- **53%** of adolescents and **40%** of adult women at risk of unintended pregnancy are not using a most or moderately effective contraceptive method.

The average American woman becomes sexually active at age **17** and wants two children.

She will spend approximately **4** years of her sexually active reproductive life either pregnant or trying to get pregnant, and **25+** years trying to avoid pregnancy.

Finer LB and Zolna MR, Declines in unintended pregnancy in the United States, 2008–2011, *New England Journal of Medicine*, 2016, 374(9):843–852



■ We Must Always Consider


- Culture
- Trust
- Community
- Ongoing relationships
- Legal obligations
- Our own biases





One Key Question[®]:
“Would you like to become
pregnant in the next year?”

Provider Discussions about Pregnancy Intent



Percentage who often or always discuss pregnancy motivations during follow-up contraceptive visits.

- **Why** don't doctors talk to patients about family planning?
 - Not enough time
 - Patients are there for other reasons/not on the patient's agenda
 - Didn't think of it
 - Lack of familiarity/comfort with methods
 - Underestimate risk of pregnancy
 - Discomfort with discussions about sex



➤ Are You Planning a Pregnancy in the Next Year?

YES (preconception planning)

- Lifestyle modification
- Nutrition/weight management
- Chronic disease management
- Folic acid
- Avoidance of toxins
- Vaccines

NO

- Is there any chance that you might get pregnant in the next year?
- What are you doing to prevent pregnancy?



➤ Katherine

25-years-old, presenting with cough and UTI.

Katherine is diabetic with prescribed insulin; she's not always under control.

Her latest A1C was 8.6.

You ask **One Key Question®**



Time Out to Talk



➤ Incidence of Congenital Anomalies by Exposure

- <http://www.nejm.org/doi/full/10.1056/NEJM200404083501524>
- <http://www.healthline.com/health-experts/fruit-womb/diabetes-pregnancy-11-hemoglobin-a1c-and-diabetic-control>
- <http://www.medpagetoday.com/Neurology/Seizures/3884>
- <http://emedicine.medscape.com/article/260725-overview#aw2aab6b8>

Rate	Exposure
3.4%	Low dose methotrexate
8.2%	Carbamazepine
10.7%	Phenytoin
12.5%	ACE-I
5%	Hgb A1C 6.9-8.8
16.3%	Methamphetamine use
20.3%	Divalproex
16%	Hgb A1C >10.4
38%	Statin
46%	Isotretinoin

➤ Best Practices for Katherine

- Ask **One Key Question®** at all visits
- Preconception counseling
- Prenatal vitamins
- Harm reduction
- Discuss diabetes control
- Review of medications



► Louise

42-years-old, with two teenagers who comes in for a routine visit and believes she is peri-menopausal.

BP 148/92

You ask **One Key Question®**



Time Out to Talk



HOW WELL DOES BIRTH CONTROL WORK?



Really, really well



The Implant
(Nexplanon)

Works, hassle-free, for up to...

3 years



IUD
(Skyla)

3 years



IUD
(Mirena)

5 years



IUD
(ParaGard)

12 years

No
hormones



Sterilization,
for men and women

Forever

What is your chance
of getting pregnant?



Less than 1 in 100 women



Okay



The Pill

For it to work best, use it...

Every. Single. Day.



The Patch

Every week



The Ring

Every month



The Shot
(Depo-Provera)

Every 3 months



6-9 in 100 women,
depending on method



Not so well



Withdrawal



Diaphragm



Fertility
Awareness




Condoms,
for men and women

Needed
for STI
protection

Use with
any other
method

For each of these methods to work, you or your partner have to use it every single time you have sex.



12-24 in 100 women,
depending on method

FYI, without birth control,
over 90 in 100 young women
get pregnant in a year.

What is Needed Before Prescribing Combined Hormonal Contraceptives?

REQUIRED	RECOMMENDED	NOT REQUIRED
Medical history Blood pressure	BMI	Pap Pelvic exam STI testing Hemoglobin

US Selected Practice Recommendations for Contraception Use. CDC, 2016.

Stewart F, et al. Clinical breast and pelvic examination requirements for hormonal contraception: Current practice vs evidence. *JAMA*. 2001;285:2232-9.



Summary Chart of U.S. Medical Eligibility Criteria for Contraceptive Use

Condition	Sub-Condition	Cu-IUD		LNG-IUD		Implant		DMPA		POP		CHC	
		I	C	I	C	I	C	I	C	I	C	I	C
Age		Menarche to <20 yrs:2	Menarche to <20 yrs:2	Menarche to <18 yrs:1	Menarche to <18 yrs:2	Menarche to <18 yrs:1	Menarche to <18 yrs:2	Menarche to <18 yrs:1	Menarche to <18 yrs:2	Menarche to <18 yrs:1	Menarche to <18 yrs:2	Menarche to <40 yrs:1	Menarche to <40 yrs:1
		≥20 yrs:1	≥20 yrs:1	18-45 yrs:1	18-45 yrs:1	18-45 yrs:1	18-45 yrs:1	18-45 yrs:1	18-45 yrs:1	18-45 yrs:1	18-45 yrs:1	≥40 yrs:2	≥40 yrs:2
				>45 yrs:1	>45 yrs:2	>45 yrs:1	>45 yrs:2	>45 yrs:1	>45 yrs:2	>45 yrs:1	>45 yrs:2		
Anatomical abnormalities	a) Distorted uterine cavity	4	4										
	b) Other abnormalities	2	2										
Anemias	a) Thalassemia	2	1	1	1	1	1	1	1	1	1	1	1
	b) Sickle cell disease [†]	2	1	1	1	1	1	1	1	1	1	2	2
	c) Iron-deficiency anemia	2	1	1	1	1	1	1	1	1	1	1	1
Benign ovarian tumors	(including cysts)	1	1	1	1	1	1	1	1	1	1	1	1
Breast disease	a) Undiagnosed mass	1	2	2*	2*	2*	2*	2*	2*	2*	2*	2*	2*
	b) Benign breast disease	1	1	1	1	1	1	1	1	1	1	1	1
	c) Family history of cancer	1	1	1	1	1	1	1	1	1	1	1	1
	d) Breast cancer [†]												
	i) Current	1	4	4	4	4	4	4	4	4	4	4	4
Breastfeeding	ii) Past and no evidence of current disease for 5 years	1	3	3	3	3	3	3	3	3	3	3	3
	a) <21 days postpartum					2*	2*	2*	2*	2*	2*	4*	4*
	b) 21 to <30 days postpartum												
	i) With other risk factors for VTE					2*	2*	2*	2*	2*	2*	3*	3*
	ii) Without other risk factors for VTE					2*	2*	2*	2*	2*	2*	3*	3*
	c) 30-42 days postpartum												
	i) With other risk factors for VTE					1*	1*	1*	1*	1*	1*	3*	3*
	ii) Without other risk factors for VTE					1*	1*	1*	1*	1*	1*	2*	2*
	d) >42 days postpartum					1*	1*	1*	1*	1*	1*	2*	2*
	Awaiting treatment	4	2	4	2	2	2	2	2	1	1	2	2
Cervical cancer		4	2	4	2	2	2	2	2	1	1	2	2
Cervical ectropion		1	1	1	1	1	1	1	1	1	1	1	1
Cervical intraepithelial neoplasia		1	2	2	2	2	2	2	2	1	1	2	2
Cirrhosis	a) Mild (compensated)	1	1	1	1	1	1	1	1	1	1	1	1
	b) Severe [†] (decompensated)	1	3	3	3	3	3	3	3	3	3	4	4
Cystic fibrosis [†]		1*	1*	1*	1*	2*	2*	1*	1*	1*	1*	1*	1*
Deep venous thrombosis (DVT)/Pulmonary embolism (PE)	a) History of DVT/PE, not receiving anticoagulant therapy												
	i) Higher risk for recurrent DVT/PE	1	2	2	2	2	2	2	2	2	2	4	4
	ii) Lower risk for recurrent DVT/PE	1	2	2	2	2	2	2	2	2	2	3	3
	b) Acute DVT/PE	2	2	2	2	2	2	2	2	2	2	4	4
	c) DVT/PE and established anticoagulant therapy for at least 3 months												
	i) Higher risk for recurrent DVT/PE	2	2	2	2	2	2	2	2	2	2	4*	4*
	ii) Lower risk for recurrent DVT/PE	2	2	2	2	2	2	2	2	2	2	3*	3*
	d) Family history (first-degree relatives)	1	1	1	1	1	1	1	1	1	1	2	2
	e) Major surgery												
	i) With prolonged immobilization	1	2	2	2	2	2	2	2	2	2	4	4
	ii) Without prolonged immobilization	1	1	1	1	1	1	1	1	1	1	2	2
	f) Minor surgery without immobilization	1	1	1	1	1	1	1	1	1	1	1	1
		1*	1*	1*	1*	1*	1*	1*	1*	1*	1*	1*	1*
		1*	1*	1*	1*	1*	1*	1*	1*	1*	1*	1*	1*

Key:

Condition	Sub-Condition	Cu-IUD		LNG-IUD		Implant		DMPA		POP		CHC	
		I	C	I	C	I	C	I	C	I	C	I	C
Diabetes	a) History of gestational disease	1	1	1	1	1	1	1	1	1	1	1	1
	b) Nonvascular disease												
	i) Non-insulin dependent	1	2	2	2	2	2	2	2	2	2	2	2
	ii) Insulin dependent	1	2	2	2	2	2	2	2	2	2	2	2
	c) Nephropathy/retinopathy/neuropathy [†]	1	2	2	2	2	2	3	3	2	2	3/4*	3/4*
	d) Other vascular disease or diabetes of >20 years' duration [†]	1	2	2	2	2	2	3	3	2	2	3/4*	3/4*
Dysmenorrhea	Severe	2	1	1	1	1	1	1	1	1	1	1	1
Endometrial cancer [†]		4	2	4	2	1	1	1	1	1	1	1	1
Endometrial hyperplasia		1	1	1	1	1	1	1	1	1	1	1	1
Endometriosis		2	1	1	1	1	1	1	1	1	1	1	1
Epilepsy [†]	(see also Drug Interactions)	1	1	1*	1*	1*	1*	1*	1*	1*	1*	1*	1*
Gallbladder disease	a) Symptomatic												
	i) Treated by cholecystectomy	1	2	2	2	2	2	2	2	2	2	2	2
	ii) Medically treated	1	2	2	2	2	2	2	2	2	2	3	3
	iii) Current	1	2	2	2	2	2	2	2	2	2	3	3
	b) Asymptomatic	1	2	2	2	2	2	2	2	2	2	2	2
	a) Suspected GTD (immediate postevacuation)												
	i) Uterine size first trimester	1*	1*	1*	1*	1*	1*	1*	1*	1*	1*	1*	1*
	ii) Uterine size second trimester	2*	2*	2*	2*	1*	1*	1*	1*	1*	1*	1*	1*
	b) Confirmed GTD												
	i) Undetectable/non-pregnant β-hCG levels	1*	1*	1*	1*	1*	1*	1*	1*	1*	1*	1*	1*
Gestational trophoblastic disease [†]	ii) Decreasing β-hCG levels	2*	1*	2*	1*	1*	1*	1*	1*	1*	1*	1*	1*
	iii) Persistently elevated β-hCG levels or malignant disease, with no evidence or suspicion of intrauterine disease	2*	1*	2*	1*	1*	1*	1*	1*	1*	1*	1*	1*
	iv) Persistently elevated β-hCG levels or malignant disease, with evidence or suspicion of intrauterine disease	4*	2*	4*	2*	1*	1*	1*	1*	1*	1*	1*	1*
	a) Nonmigraine (mild or severe)	1	1	1	1	1	1	1	1	1	1	1	1
	b) Migraine												
	i) Without aura (includes menstrual migraine)	1	1	1	1	1	1	1	1	1	1	2*	2*
	ii) With aura	1	1	1	1	1	1	1	1	1	1	4*	4*
	a) Restrictive procedures	1	1	1	1	1	1	1	1	1	1	1	1
	b) Malabsorptive procedures	1	1	1	1	1	1	1	1	3	3	COCs: 3	COCs: 3
												P/R: 1	P/R: 1
History of bariatric surgery [†]	a) Pregnancy related	1	1	1	1	1	1	1	1	1	1	2	2
	b) Past COC related	1	2	2	2	2	2	2	2	2	2	3	3
History of cholestasis													
History of high blood pressure during pregnancy		1	1	1	1	1	1	1	1	1	1	2	2
History of Pelvic surgery		1	1	1	1	1	1	1	1	1	1	1	1
HIV	a) High risk for HIV	2	2	2	2	1	1	2*	2*	1	1	1	1
	b) HIV infection					1*	1*	1*	1*	1*	1*	1*	1*
	i) Clinically well receiving ARV therapy	1	1	1	1	If on treatment, see Drug Interactions							
	ii) Not clinically well or not receiving ARV therapy [†]	2	1	2	1	If on treatment, see Drug Interactions							

Abbreviations: C=continuation of contraceptive method; CHC=combined hormonal contraception (pill, patch, and, ring); COC=combined oral contraceptive; Cu-IUD=copper-containing

Summary Chart of U.S. Medical Eligibility Criteria

Condition	Sub-Condition	Cu-IUD		LNG-IUD		Implant		DMPA		POP		CHC	
		I	C	I	C	I	C	I	C	I	C	I	C
Hypertension	a) Adequately controlled hypertension	1*		1*		1*		2*		1*		3*	
	b) Elevated blood pressure levels (properly taken measurements)												
	i) Systolic 140-159 or diastolic 90-99	1*		1*		1*		2*		1*		3*	
	ii) Systolic ≥160 or diastolic ≥100 [†]	1*		2*		2*		3*		2*		4*	
	c) Vascular disease	1*		2*		2*		3*		2*		4*	
Inflammatory bowel disease	(Ulcerative colitis, Crohn's disease)	1		1		1		2		2		2/3*	
Ischemic heart disease [†]	Current and history of	1		2	3	2	3	3		2	3	4	
Known thrombogenic mutations [†]		1*		2*		2*		2*		2*		4*	
Liver tumors	a) Benign												
	i) Focal nodular hyperplasia	1											
	ii) Hepatocellular adenoma [†]	1											
	b) Malignant [†] (hepatoma)	1											
Malaria		1											
Multiple risk factors for atherosclerotic	(e.g., older age, smoking, diabetes, hypertension, low HDL, high LDL, or high	1											
		1 2 3 4											
		No restriction for the use of the contraceptive method for a woman with that condition Advantages of using the method generally outweigh the theoretical or proven risks Theoretical or proven risks of the method usually outweigh the advantages – not usually recommended unless more appropriate methods are not available or acceptable Unacceptable health risk if the contraceptive method is used by a woman with that condition											

https://www.cdc.gov/reproductivehealth/unintendedpregnancy/pdf/legal_summary-chart_english_final_tag508.pdf





But, what about
last night's
unprotected sex?

OOPS! EMERGENCY CONTRACEPTION: BIRTH CONTROL THAT WORKS *AFTER* SEX

Types of emergency contraception	How well does it work?	How soon do I have to use it?	How do I use it?	Where can I get it?
 ParaGard IUD	Almost 100% effective 	Within 5 days 	It's placed in the uterus by a doctor or nurse  Keeps working as super effective birth control.	From a doctor, nurse, or at a clinic  Say it's for EC so you are scheduled quickly.
 Ella	 Less effective if over 195 pounds. Try an IUD. 	ASAP  Works better the sooner you take it, up to 5 days.	Take the pill as soon as you get it  Remember to use it every time you have unprotected sex.	From a doctor, nurse, or at a clinic  Get an extra pack for future emergencies.
 Plan B One-Step or a generic	 Less effective if over 165 pounds. Try ella or an IUD. 	ASAP  Works better the sooner you take it, up to 3 days.	Take the pill as soon as you get it  Remember to use it every time you have unprotected sex.	At a pharmacy, no prescription needed  Get an extra pack for future emergencies.

Emergency Contraception

FOR _____ DATE _____
 ADDRESS _____
 REFILL _____ TIMES

R_x

**Ulipristal 1 tab PO x 1
 within 120 hours of
 unprotected intercourse.**

DISPENSE AS WRITTEN PRODUCT SELECTION PERMITTED

DEA NO. _____ ADDRESS _____

Reorder Item #6100 Total Pharmacy Supply, Inc 1-800-878-2822



FOR _____ DATE _____
 ADDRESS _____
 REFILL _____ TIMES

R_x

**Levonorgestrel 1.5mg 1
 tab PO x 1 ASAP within
 120 hours (best within
 72 hours) of unprotected
 intercourse.**

DISPENSE AS WRITTEN PRODUCT SELECTION PERMITTED


DEA NO. _____ ADDRESS _____

Reorder Item #6100 Total Pharmacy Supply, Inc 1-800-878-2822





BMI Does Matter



Efficacy of hormonal EC by BMI *

(Pregnancy rate (%))

BMI Kg/m2	Ulipristal Acetate (UPA)	LNG-EC*
<25	1.1	1.3
25-29.9	1.1	2.5
>30	2.6	5.8

* Average expected pregnancy rate with no EC = 6.2-7.4 percent.



➤ Best Practices for Louise

- Ask **One Key Question**® at all visits
- Incorporate patient-centered counseling and, when appropriate, consider tiered-effectiveness when discussing contraceptive options for patients
- Always consult the MEC when prescribing birth control
- Don't coerce her
- Offer emergency contraception and condoms




➤ Michael

18-years-old, a high school student, who comes to you because his girlfriend of four months told him she tested positive for chlamydia.

After reviewing presumptive treatment and discussing ways to reduce future risk of STI transmission ...

You ask **One Key Question®**



Time Out to Talk



Why Should We Ask Men?

- Men who are educated about reproductive health issues are more likely to support their partners in decisions on contraceptive use and family planning.
- Men who are knowledgeable about reproductive health issues and can communicate about them with their partners, are more likely to be supportive during pregnancy and may make better health care decisions.



Taking a Sexual History

- If we know what kinds of behaviors our patients are engaging in, we can better address their health needs and provide them with individualized advice.
 - Engaging adolescent men is especially important as this age demographic rarely discusses sexual and reproductive health with their physicians.
 - Provides an important opportunity to provide accurate information, as well as guidance on everything from negotiating consent to decreasing risk of an unintended pregnancy or STI.



➤ Anne

17-years-old, thinks she needed an appointment to renew her birth control prescription before she heads to college next month.


You ask **One Key Question®**



Time Out to Talk



Pill-users Who Missed a Dose in the Past Three Months



FACT SHEET : THE PILL

Remember, the pill **does not** protect you from Sexually Transmitted Infections or HIV. Always use condoms to protect yourself!



HOW DO BIRTH CONTROL PILLS WORK?

- Birth control pills contain hormones like the ones your body makes. These hormones stop your ovaries from releasing eggs. Without an egg, you cannot get pregnant.
- No method of birth control is 100% effective. If you take all of your birth control pills on time, they are 99% effective. If you skip some pills, they are 91% effective.

HOW DO I START THE PILL?

- There are 2 ways to start the pill:
 - **Quick Start:** Take your first pill as soon as you get the pack.
 - **Next period:** Take your first pill soon after your next period begins.
- If you take your first pill *up to 5 days after the start of your period*, you are protected against pregnancy **right away**.
- If you take your first pill *more than 5 days after the start of your period*, you should **use condoms as back-up for the first 7 days**.

HOW DO I USE THE PILL?

- **Once you start using the pill**, take 1 pill each day. Take your pill at the same time each day.
- After you finish a pack of pills, you should start a new pack the next day. You should have **NO day without a pill**.

WHAT IF I MISS PILLS?

- **I forgot ONE pill:** Take your pill as soon as you can.
- **I forgot TWO pills or more:** Take your pill as soon as you can. Take your next pill at the usual time. **Use condoms for 7 days. Use emergency contraception (EC) if you have unprotected sex.**

WHAT IF I STOPPED TAKING THE PILL AND HAD UNPROTECTED SEX?

- Take Emergency Contraception (EC) **right away**. EC can prevent pregnancy up to 5 days after sex, and it works better the sooner you take it.

HOW DOES THE PILL HELP ME?

- The pill is safe and effective birth control.
- Your periods may be more regular, lighter, and shorter. You may have clearer skin.
- The pill lowers your risk of getting cancer of the uterus and ovaries.
- The pill has **no effect** on your ability to get pregnant in the future, after you stop taking it.

HOW WILL I FEEL ON THE PILL?



- 1 IUD used for 3 years = 1,095 pills
- 1 IUD used for 5 years = 1,826 pills
- 1 IUD used for 10 years = 3,650 pills



➤ One Year Failure Rates

Effectiveness	Contraceptive	Typical-Use Pregnancy Rate
Ineffective	Chance	85%
Less effective	Condoms	18%
More effective	Pill/patch/ring	9%
	Injectable	6%
Highly effective	IUDs	0.2-8%
	Sterilization	0.15-0.5%
	Implant	0.05%






Copper IUD



Progestin IUDs



	Copper IUD	Progestin IUDs
Brand names	ParaGard®	Mirena®, Skyla®, Liletta®, and others
When does the IUD start working?	The copper IUD starts working right away.	The progestin IUDs start working 7 days after they are inserted. Use condoms or another back-up method of birth control for the first 7 days after the IUD is inserted to prevent pregnancy.
How long can you use it?	ParaGard® works for 12 years. Your health care provider can remove your IUD at any time.	May be left in place from 3 to 7 years, depending on which IUD you choose. Your health care provider can remove your IUD at any time.
Does it contain hormones?	No.	Yes. There is a low dose of progestin but no estrogen.

A Word about IUD Costs ...

Based on full price, without insurance assistance *

IUD	Full Price Range	Cost/month for one year	Cost/month for five years
Mirena® or Kyleena®	\$500-\$858	\$41-\$72	\$8-\$14
ParaGard®	\$500-\$739	\$41-\$62	\$8-\$12 \$4-\$6 (Cost/month for 10 years)
Skyla®	\$650-\$714	\$54-\$60	\$18-\$20 (Three Years)
Liletta®	\$50-\$684	\$4-57	\$1-\$19 (Three Years)

Liletta® can be purchased by FQHCs and other clinics who use 340B pricing for ~\$50. Mirena® can cost upwards of \$600 even with 340B pricing.

<https://www.bedsider.org/methods/iud#costs>



➤ Best Practices for Anne

- Ask **One Key Question**® at all visits
- Use patient-centered counseling to identify barriers and solutions for patients
- Offer same-day LARC insertion





Wrapping Up

Rapid Fire Myth-Busting:
Is it a Fact or a Myth?



It is evidence-based to place an IUD in a nulliparous non-monogamous teen.

FACT



A history of PID (such as Gonorrhea and/or Chlamydia) is an absolute contraindication to IUD insertion.

MYTH



**Contraceptive use does not affect fertility and
will not make it “harder” to get pregnant in
the future.**

FACT



**Intrauterine contraceptives increase the risk
of ectopic pregnancy.**

MYTH



**Amenorrhea caused by continuous use of
contraception is associated with major
depressive disorder.**

MYTH



Continuous use of OCPs is safe for patients.

FACT



It's important to check a patient's blood pressure before prescribing birth control pills.

FACT



Long term use of depot medroxyprogesterone acetate (DMPA) is associated with an increased risk of femoral neck fractures.

MYTH



**42% of family planning providers use IUDs,
compared to 12% of the general population.**

FACT



**Depot medroxyprogesterone acetate (DMPA)
is too dangerous for teens.**

MYTH



Transgender men and women have sexual and reproductive healthcare needs that can be met in a family medicine clinic.

FACT



**The placement of IUDs increase the risk of
abortion.**

MYTH



**The CDC MEC provides evidence-based
recommendations about birth control
prescriptions.**

FACT



**Liletta® does NOT have bio-equivalency to
Mirena®.**

MYTH




Scheduled bleeding every four weeks on combined hormonal contraceptives is the same thing as a period.

MYTH




Best Practices



LEARNER SELF-ASSESSMENT

You are encouraged to participate in this online assessment. The knowledge and attitude assessment will give you a sense of practice gaps and assist you in planning educational interventions to close the gaps. Colleagues from every state will be participating, and you'll be able to see where you fall in the scoring. The assessment also includes the correct answers and all citations and rationales. The LSA is sponsored for .25 AAFP Prescribed or *AMA PRA Category 1 credits™* and is free to all health care clinicians.

[GO TO ASSESSMENT](#)

Designed
for family physicians ...
by family physicians

www.familydocs.org/rhi

MAINTENANCE OF CERTIFICATION

CAFP, in partnership with Interstate Postgraduate Medical Association, has developed an ABFM Part IV [Improving Performance in Practice module](#). This module is designed to increase the use of One Key Question® for reproductive health planning, enhance physician-patient communication, and improve team approaches to care. The module is approved for ABFM Part IV credit, includes 30 AAFP Prescribed credits upon completion and is based on a team-approach [*AMA PRA Category 1™* credit also is available]. The Part IV module is appropriate for any family physician, family medicine resident or other primary care physician plus your teammates. Questions? Contact Shelly Rodrigues at srodrigues@familydocs.org.

[GO TO MODULE](#)



What Tools and Resources are Available?

Start at www.familydocs/rhi

- OneKeyQuestion
- Bedsider.org
- www.reproductiveaccess.org
- Contraception Point-Of-Care app (Android and IOS)
- CDC US Medical Eligibility for Contraceptive Use
- <https://wwwn.cdc.gov/pubs/CDCInfoOnDemand.aspx?ProgramID=195> (for add'l free handouts)



Thank You
Questions?

References

- www.bedside.org
- <https://powertodecide.org/select360-consulting>
- Finer LB and Zolna MR, Declines in unintended pregnancy in the United States, 2008–2011, *New England Journal of Medicine*, 2016, 374(9):843-852, <http://nejm.org/doi/full/10.1056/NEJMsa1506575>.
- https://www.guttmacher.org/sites/default/files/report_pdf/improvingcontraceptiveuse_0.pdf
- Studies in Family Planning. Population Council. Vol 39 No 1 Mar 2008
- <http://www.nejm.org/doi/full/10.1056/NEJM200404083501524>
- <http://www.healthline.com/health-experts/fruit-womb/diabetes-pregnancy-11-hemoglobin-a1c-and-diabetic-control>
- <http://www.medpagetoday.com/Neurology/Seizures/3884>
- <http://emedicine.medscape.com/article/260725-overview#aw2aab6b8>
- US Selected Practice Recommendations for Contraception Use. CDC, 2016.
- Stewart F, et al. Clinical breast and pelvic examination requirements for hormonal contraception: Current practice vs evidence. *JAMA*. 2001;285:2232-9.
- https://www.cdc.gov/reproductivehealth/unintendedpregnancy/pdf/legal_summary-chart_english_final_tag508.pdf
- Bissel et al. Supplying emergency contraception via community pharmacies in the UK: reflections on the experiences of users and providers. *Soc Sci Med*.2003;57:2367-2378.
- Raine et al. Direct access to emergency contraception through pharmacies and effect on unintended pregnancy and STIs: a randomized controlled trial. *JAMA*.2005;293:54-62.
- Trussell J, Koenig J, Ellertson C, Stewart F. Preventing unintended pregnancy: the cost-effectiveness of three methods of emergency contraception. *Am J Public Health* 1997;87:932-7.
- Gold, MA, Wolford JE, Smith KA, Parker AM The effects of advance prescription of emergency contraception on adolescent women's sexual and contraceptive behaviors. *J Pediatr Adolesc Gynecology* 17(2):87-96.



- [Glasier A, Cameron ST, Blithe D, et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Feb 2011, 84\(2011\): 363-367.](#)
- Trussell, J. "Contraceptive Failures in the US." *Contraception*, 2011.
- Sivin, et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDs. *Contraception*. 1991 Nov;44(5):473-80.
- Chiou CF, Trussell J, Reyes E, Knight K, Wallace J, Udani J, Oda K, Borenstein J. Economic analysis of contraceptives for women. *Contraception*. 2003;68(1):3-10.
- Hubacher D, Cheng D. Intrauterine devices and reproductive health: American women in feast and famine. *Contraception*. 2004 Jun;69(6):437-46.
- Hatcher RA, Ziemann M et al. *A Pocket Guide to Managing Contraception*. Tiger, Georgia: Bridging the Gap Foundation, 2004
- Grimes DA. Intrauterine device and upper-genital-tract infection. *Lancet*. 2000 Sep 16;356(9234):1013-9.
- Andersson K, Odland V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. *Contraception*. 1994 Jan;49(1):56-72.
- Grimes D, et al, Immediate post-partum insertion of intrauterine devices, *Cochrane* 2003 (1).
- Hubacher D et al. Use of copper IUDs and the risk of infertility among nulligravid women *NEJM*, 2001, 108;304-14.
- Grimes DA, Schulz KF. Antibiotic prophylaxis for intrauterine contraceptive device insertion. *Cochrane Database Syst Rev*. 2001;(1):CD001327.
- Selected practice recommendations for contraceptive Use, 2nd edition, Geneva: WHO 2005.
- <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2588420/>
- Stewart F, et al. Clinical breast and pelvic examination requirements for hormonal contraception: Current practice vs evidence. *JAMA*. 2001;285:2232-9.
- ACOG Committee Opinion. No 602, June 2014, reaffirmed 2016.
- (<https://www.contraceptionjournal.org/article/S0010-7824%2815%2900072-4/pdf>)





Repro Health Happy Hour

NMAFP Winter Refresher

February 23 @ 5:00pm

Garduño's Restaurant | Hotel Albuquerque

Please join the New Mexico Cluster of the Reproductive Health Access Network for a social hour at NMAFP's Winter Refresher.

This is a great opportunity to connect with supportive colleagues, discuss Academy activities, and gear up for an energized 2019!



reproductive
health
access
network
new mexico

Sponsored by the Reproductive Health Access Project